Erdafitinib: all 36 studies that test it

Page 1 of 1. Open to participants first (2), then studies with results posted, then the rest; newest registration first within each.

• Drug Screening Using IMD in Bladder CancerEnrolling by invitationNCT06204614Early Phase 1
• The Drug Rediscovery Protocol (DRUP Trial)RecruitingNCT02925234Phase 2
• Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Mutations or Fusions (MATCH - Subprotocol K2)Active, not recruitingNCT06351371Phase 2Results posted
• Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Amplifications (MATCH-Subprotocol K1)Active, not recruitingNCT06308822Phase 2Results posted
• A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)CompletedNCT04172675Phase 2Results posted
• A Study of Erdafitinib in Participants With Advanced Solid Tumors and Fibroblast Growth Factor Receptor (FGFR) Gene AlterationsCompletedNCT04083976Phase 2Results posted
• Erdafitinib and Abiraterone Acetate or Enzalutamide in Treating Patients With Double Negative Prostate CancerTerminatedNCT03999515Phase 2Results posted
• A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene AberrationsActive, not recruitingNCT03390504Phase 3Results posted
• Fulvestrant, Palbociclib and Erdafitinib in ER+/HER2-/FGFR-amplified Metastatic Breast CancerCompletedNCT03238196Phase 1Results posted
• Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)Active, not recruitingNCT03210714Phase 2Results posted
• Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)Active, not recruitingNCT03155620Phase 2Results posted
• An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial CancerActive, not recruitingNCT02365597Phase 2Results posted
• Erdafitinib in Metastatic Steroid-cell Ovarian CancerCompletedNCT06328491Not applicable
• Testing the Anti-cancer Drug Erdafitinib for Brain Cancers That Have Returned or Progressed Following TreatmentActive, not recruitingNCT05859334Phase 2
• A Study of Erdafitinib Intravesical Delivery System in Japanese Participants With Bladder CancerActive, not recruitingNCT05567185Phase 1
• Study of Erdafitinib Intravesical Delivery System for Localized Bladder CancerActive, not recruitingNCT05316155Phase 1/2
• Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and ImmunotherapyActive, not recruitingNCT04963153Phase 1
• A Study of Oral Erdafitinib in People With Recurrent Non-Invasive Bladder CancerActive, not recruitingNCT04917809Phase 2
• Erdafitinib for the Treatment of Patients With Castration-Resistant Prostate CancerTerminatedNCT04754425Phase 2
• A Study of Steady-state Carbamazepine on the Single-dose of Erdafitinib Tablets in Healthy Adult ParticipantsCompletedNCT04330248Phase 1
• FGFR Inhibitor in FGFR Dysregulated CancerTerminatedNCT03827850Phase 2
• Myeloma-Developing Regimens Using Genomics (MyDRUG)CompletedNCT03732703Phase 1/2
• A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of ErdafitinibTerminatedNCT03587363Phase 1
• A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of JNJ-63723283, an Anti-Programmed Cell Death (PD)-1 Monoclonal Antibody, as Monotherapy or in Combination With Erdafitinib in Japanese Participants With Advanced Solid CancersCompletedNCT03547037Phase 1
• A Study to Evaluate the Effect of Fluconazole and Itraconazole on Erdafitinib Pharmacokinetics in Healthy Adult ParticipantsCompletedNCT03135106Phase 1
• A Study to Determine the Effect of Food on the Pharmacokinetics of Erdafitinib in Healthy ParticipantsCompletedNCT03066687Phase 1
• Testing JNJ-42756493 In Combination With Dexamethasone in Multiple Myeloma That Came Back After a Period of ImprovementTerminatedNCT02952573Phase 2
• A Study to Evaluate the Clinical Efficacy of JNJ-42756493 (Erdafitinib), A Pan-Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor, In Asian Participants With Advanced Non-Small-Cell Lung Cancer, Urothelial Cancer, Esophageal Cancer Or CholangiocarcinomaCompletedNCT02699606Phase 2
• A Study to Assess the Absorption, Metabolism, and Routes of Excretion Following Oral Administration of (14C) Radiolabeled JNJ--42756493 to Healthy Male ParticipantsCompletedNCT02692677Phase 1
• A Study to Assess the Relative Bioavailability of JNJ-42756493 TabletsCompletedNCT02466815Phase 1
• Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)Active, not recruitingNCT02465060Phase 2
• Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 (Erdafitinib) in Participants With Advanced Hepatocellular CarcinomaCompletedNCT02421185Phase 1/2
• Study to Assess the Relative Bioavailability of Orally Administered JNJ-42756493 Tablet Versus JNJ-42756493 Capsule in Healthy ParticipantsCompletedNCT02231489Phase 1
• Pharmacokinetic Study of JNJ-42756493 in Healthy ParticipantsCompletedNCT02218073Phase 1
• A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 in Patients With Advanced or Refractory Solid Tumors or LymphomaCompletedNCT01962532Phase 1
• A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 in Adult Participants With Advanced or Refractory Solid Tumors or LymphomaCompletedNCT01703481Phase 1

← Erdafitinib overview